Cat. No. | Product name | CAS No. |
DCC1610 |
Cx1739
Novel low-impact ampakine that can safely activate AMPA receptors without causing excito-neurotoxicity, rapidly crossing the blood-brain barrier (T max = 2 min), protecting against respiratory depression |
|
DCC1611 |
Cx4338
Novel inhibitor of CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signaling |
41669-06-7 |
DCC1612 |
Cx-659s
Nonsteroidal dermatologic and anti-inflammatory agent, blocking the MEK1/2-Erk1/2 pathway, inhibiting chronic contact hypersensitivity responses (CHRs) and the rebound phenomenon following withdrawal of corticosteroid therapy without immunosuppression |
204980-81-4 |
DCC1613 |
Cxcr2 Antagonist 3e
Novel potent CXCR2 antagonist |
|
DCC1614 |
Cxcr2-in-c5
Novel CXCR2 selective antagonist with a low CXCR1 antagonism preference |
|
DCC1615 |
Cy 208-243
Selective D1 agonist with anti-Parkinsonian activity |
100999-26-6 |
DCC1616 |
Cyanabactin
Novel ABA receptor agonist, preferentially activating Pyrabactin Resistance 1 (PYR1) with low nanomolar potency |
2141961-23-9 |
DCC1617 |
cyanonilutamide
Androgen receptor (AR) antagonist, inhibiting AR function in castrate-resistant prostate cancer (CRPC) |
143782-20-1 |
DCC1618 |
Cyanotryptophan
Featured
Blue fluorescent amino acid, exhibiting blue fluorescence (λ max ~ 405 nm) with a high quantum yield and long lifetime |
1132749-42-8 |
DCC1619 |
Cybluc
Novel Effective Aminoluciferin Derivative for Deep Bioluminescence Imaging |
649470-26-7 |
DCC1620 |
Cyclomarin A
Natural antibacterial peptide, activating the AAA+ protease ClpC/ClpP, causing cell death by uncontrolled protein degradation |
169062-92-4 |
DCC1621 |
Cyclopeptide 66
Novel PD-1/PD-L1 inhibitor, binding two PD-L1 and efficiently block the PD-1/PD-L1 interaction |
|
DCC1622 |
Cyclophostin
Natural irreversible inhibitor of acetylcholinesterase (AChE) |
144773-26-2 |
DCC1623 |
Cyclorasin B4-27
Novel bicyclic peptidyl pan-Ras inhibitor, binding selectively to the GTP-bound forms of wild-type and mutant Ras isoforms (K D = 21 nM for KRasG12V-GppNHp) and being highly cell-permeable and metabolically stable (serum t1/2 > 24 h) |
|
DCC1624 |
Cyclo-sgwif(4-cl)wav
Novel Cyclic Peptide Inhibitor of the p6/UEV Protein-Protein Interaction, disrupting the p6/UEV interaction with an IC50 of 6.17 ± 0.24 μM by binding to UEV with a Kd of 11.9 ± 2.8 μM. |
|
DCC1625 |
Cyclosporin E
Immunosuppressant |
63798-73-2 |
DCC1626 |
Cyclosporin L
Immunosuppressant |
108027-39-0 |
DCC1627 |
Cyclosporin O
Macrocyclic immunosuppressive peptide, exhibiting a higher plasma concentration than Cyclophilin A |
|
DCC1628 |
Cyclosporine G
immunosuppressive agent |
74436-00-3 |
DCC1629 |
Cycluc12
Cyclic alkylaminoluciferin substrate for firefly luciferase |
1627696-39-2 |
DCC1630 |
Cycluc2
Cyclic alkylaminoluciferin substrate for firefly luciferase, emitting 4.7-fold more light than aminoluciferin, and 2.6-fold more light than D-luciferin |
1247879-17-9 |
DCC1631 |
cgs-27023
Non-peptidic, potent, and orally active stromelysin inhibitor; |
161314-70-1 |